Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Janet M. Griffiths"'
Autor:
Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Teresa Piechowiak, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS),
Externí odkaz:
https://doaj.org/article/03dab2a3f7ba4d9b9f320bbf91dd8b36
Autor:
Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologic
Externí odkaz:
https://doaj.org/article/1d95b73b0f56448095c718271556d711
Autor:
Sarah, Diver, Sriram, Sridhar, Latifa C, Khalfaoui, Richard J, Russell, Claire, Emson, Janet M, Griffiths, Melissa, de Los Reyes, Da, Yin, Gene, Colice, Christopher E, Brightling
Publikováno v:
Journal of Allergy and Clinical Immunology. 150:830-840
Understanding how asthma biomarkers relate to gene expression signatures could help identify drivers of pathogenesis.This post hoc exploratory analysis of the phase II tralokinumab trial MESOS (ClinicalTrials.gov identifier NCT02449473) aimed to prof
Autor:
Jonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, Elliot Israel, Stephanie Korn, Bill Cook, Christopher S Ambrose, Åsa Hellqvist, Stephanie L Roseti, Nestor A Molfino, Jean-Pierre Llanos, Neil Martin, Karin Bowen, Janet M Griffiths, Jane R Parnes, Gene Colice
Publikováno v:
American Journal of Respiratory and Critical Care Medicine.
Autor:
Jonathan, Corren, Tuyet-Hang, Pham, Esther, Garcia Gil, Kinga, Sałapa, Pin, Ren, Jane R, Parnes, Gene, Colice, Janet M, Griffiths
Publikováno v:
Allergy. 77:1786-1796
Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adu
Autor:
Jonathan Corren, Christopher S. Ambrose, Janet M. Griffiths, Åsa Hellqvist, Andrew W. Lindsley, Jean‐Pierre Llanos, Gene Colice, Andrew Menzies‐Gow
Publikováno v:
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical ImmunologyREFERENCES.
Allergic asthma is the most common phenotype among patients with severe asthma. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab significantly reduced the annualized asthma exacerbation rate (AAER) versus placebo in patients with severe, unc
Publikováno v:
Annals of Allergy, Asthma & Immunology. 127:689-691
Autor:
Michael E. Wechsler, Elliot Israel, Primal Kaur, Janet M. Griffiths, Christopher E. Brightling, Arnaud Bourdin, Andrew Menzies-gow, Gene L. Colice, Geoffrey Chupp, Gun Almqvist, Jonathan Corren, Karin Bowen, Sandhia Ponnarambil, Åsa Hellqvist
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (19), pp.1800-1809. ⟨10.1056/NEJMoa2034975⟩
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (19), pp.1800-1809. ⟨10.1056/NEJMoa2034975⟩
International audience; BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patient
Autor:
Esther Garcia Gil, Jane R. Parnes, Jonathan Corren, Rene van der Merwe, Janet M. Griffiths, Kinga Sałapa, Sean O'Quinn
Publikováno v:
Annals of Allergy, Asthma & Immunology. 126:187-193
Background Patients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced exacerbations by up to 71% an
Publikováno v:
Expert Opinion on Therapeutic Targets. 24:777-792
Thymic stromal lymphopoietin (TSLP), an epithelial cytokine (alarmin), is a central regulator of the immune response to inhaled environmental insults such as allergens, viruses and pollutants, initiating a cascade of downstream inflammation. There is